glp 1 colon cancer GLP-1 Receptor Agonists Reduce Colorectal Risk in IBD Populations If you are taking a

By Amina Niasse NEW YORK, June 2 (Reuters) - Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee health plan

Shop Triquetra - GLP-Activate at GNC today

All Day

However, existing evidence remains inconclusive

Reduces appetite aids weight loss Common Drugs (Examples) Exenatide Liraglutide Dulaglutide Semaglutide Lixisenatide Clinical Uses Type 2 Diabetes Mellitus (as monotherapy or combination) Obesity / weight management (especially semaglutide, liraglutide) Cardiovascular benefit: reduces major adverse CV events in T2DM with CVD Administration Subcutaneous injection (daily or weekly depending on formulation) Oral semaglutide available for some patients Adverse Effects Gastrointestinal: nausea, vomiting, diarrhea Risk of pancreatitis (rare but serious) Mild hypoglycemia if combined with sulfonylureas or insulin Injection site reactions Contraindications / Precautions Personal/family history of medullary thyroid carcinoma History of multiple endocrine neoplasia syndrome type 2 (MEN2) Severe gastrointestinal disease (gastroparesis) GLP-1 agonists = incretin mimetics